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expression of the putative tumor suppressor
genes FHIT, WWOX, FUS1 and PTEN in clinical
tumor samples
David J Stewart1*, Maria I Nunez2, Jaroslav Jelinek3, David Hong2, Sanjay Gupta2, Marcelo Aldaz4, Jean-Pierre Issa3†,
Razelle Kurzrock5† and Ignacio I Wistuba2†Abstract
Background: Since tumor suppressor gene function may be lost through hypermethylation, we assessed whether
the demethylating agent decitabine could increase tumor suppressor gene expression clinically. For fragile histidine
triad (FHIT), WW domain-containing oxidoreductase (WWOX), fused in sarcoma-1 (FUS1) and phosphatase and tensin
homolog (PTEN), immunohistochemistry scores from pre- and post-decitabine tumor biopsies (25 patients) were
correlated with methylation of the long interspersed nuclear element-1 (LINE-1) repetitive DNA element (as a
surrogate for global DNA methylation) and with tumor regression.
Results: With negative staining pre-decitabine (score = 0), the number of patients converting to positive staining
post-decitabine was 1 of 1 for FHIT, 3 of 6 for WWOX, 2 of 3 for FUS1 and 1 of 10 for PTEN. In tumors with low
pre-decitabine tumor suppressor gene scores (≤150), expression was higher post-treatment in 8 of 8 cases for FHIT
(P = 0.014), 7 of 17 for WWOX (P = 0.0547), 7 of 12 for FUS1 (P = 0.0726), and 1 of 16 for PTEN (P = 0.2034). If FHIT,
WWOX and FUS1 were considered together, median pre- versus post-decitabine scores were 60 versus 100 (P = 0.0002).
Overall, tumor suppressor gene expression change did not correlate with LINE-1 demethylation, although tumors
converting from negative to positive had a median decrease in LINE-1 methylation of 24%, compared to 6% in
those not converting (P = 0.069). Five of 15 fully evaluable patients had reductions in tumor diameter (range 0.2%
to 33.4%). Of these, three had simultaneous increases in three tumor suppressor genes (including the two patients
with the greatest tumor regression) compared to 2 of 10 with tumor growth (P = 0.25).
Conclusions: In tumors with low tumor suppressor gene expression, decitabine may be associated with increased
expression of the tumor suppressor genes FHIT, FUS1, and WWOX, but not PTEN.
Keywords: Decitabine, FHIT, FUS1, WWOX, PTEN, Tumor suppressor genes, LINE-1 methylationBackground
Several tumor suppressor genes have now been described,
and tumor suppressor gene silencing by mutation, dele-
tion, or hypermethylation [1,2] is an important component
of tumorigenesis. Treatment of cell lines or xenograft-
bearing animals with the demethylating agents decita-
bine and 5-azacytidine has been reported to increase* Correspondence: dstewart@toh.on.ca
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unless otherwise stated.expression of a variety of tumor suppressor genes [3-6].
Decitabine may upregulate gene expression through
both methylation-dependent and methylation-independent
mechanisms [1,2].
Decitabine is active clinically in some hematologic ma-
lignancies [7]. Administration of low doses of decitabine
daily for multiple successive days may be most effective
against hematological malignancies, and is also particularly
likely to induce DNA demethylation [7].
In patients with refractory malignancies receiving low
dose decitabine on days 1 to 5 ± days 8 to 12 each cycle,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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1, and found in patient tumors that decitabine decreased
methylation of the long interspersed nuclear element-1
(LINE-1) repetitive DNA element (as a surrogate for
global DNA methylation) [8], while it increased tumor
expression of the copper transport protein-1 (CTR1, a
copper/platinum transporter) [8], the Ras homolog gene
family member A (RhoA, an endocytosis regulator) [9],
and the reduced folate carrier-1 (RFC1, a folate trans-
porter) [9]. In pre-decitabine tumor samples, expression
of CTR1 [8] and RhoA [9] was lower and LINE-1 methyla-
tion tended to be higher in patients who were ≤3 months
versus >3 months beyond most recent prior therapy [8],
and LINE-1 methylation correlated inversely with expres-
sion of CTR1 [8] and RhoA [9].
Based on our observations with CTR1 [8], LINE-1 [8],
and RhoA [9], we then investigated whether expression
of selected tumor suppressor genes would vary with time
from last treatment, with LINE-1 methylation and with
decitabine treatment. The tumor suppressor genes assessed
were fragile histidine triad (FHIT), WW domain-containing
oxidoreductase (WWOX), fused in sarcoma-1 (FUS1) and
phosphatase and tensin homolog (PTEN).
FHIT is a proapoptotic tumor suppressor gene that en-
codes the fragile histidine triad protein (FHIT, also known
as bis-(5’-adenosyl) triphosphatase), and FHIT inactivation
or loss occurs in many tumor types [10]. Loss of FHIT
leads to alterations in the DNA damage response check-
point, resulting in increased DNA instability [11]. Loss of
FHIT expression is commonly associated with hyperme-
thylation of the gene, and frequent FHIT hypermethylation
has been reported in hepatocellular carcinomas [12], and
in carcinomas of the larynx [13], breast [14], lung [14],
cervix [15], vulva [16], and kidney [17]. The demethylating
agent decitabine may increase expression of FHIT in
cancer cell lines [3].
WWOX is a large gene spanning the chromosomal
fragile site 16D [18]. It encodes the protein WW domain-
containing oxidoreductase (WWOX) which may play a
role in apoptosis [19], cell metabolism [20], and modula-
tion of the activity of multiple interacting transcription
factors [21]. WWOX is generally strongly expressed in
various normal tissues [22], but its expression by immuno-
histochemistry (IHC) is absent or weak in many cancers
arising from tissues that generally express WWOX, in-
cluding cancers of the breast [18], ovary [23], bladder
[24], and esophagus [25], and in leukemias [19]. Expos-
ure to carcinogens such as cigarette smoking extract
can lead to downregulation of WWOX expression [24].
WWOX downregulation has been noted to occur via
promoter methylation in various malignancies [25-27],
and decitabine may restore WWOX expression [3,4].
The FUS1 gene (also known as tumor suppressor can-
didate 2 or TUSC2) is located in the chromosomal3p21.3 region. In lung cancers and various other malig-
nancies, this chromosomal region is frequently deleted
and FUS1/TUSC2 expression is often lost [28]. FUS1
functions as a tumor suppressor gene by inducing apop-
tosis through activation of the intrinsic mitochondrial-
dependent and Apaf-1-associated pathways [28]. FUS1/
TUSC2 may be hypermethylated in cancers of the head
and neck, and decitabine may reverse this hypermethy-
lation [29]. In breast cancer cell lines, decitabine in-
creased expression of FUS1/TUSC2 despite lack of gene
methylation [30], in keeping with the known ability of
decitabine to increase gene expression through both
methylation-dependent and methylation-independent
mechanisms [1,2].
PTEN functions as a tumor suppressor gene by nega-
tively regulating the Akt pathway, and it is one of the
most frequently inactivated tumor suppressor genes in
human cancers [31]. PTEN hypermethylation has been
reported to be common in several tumor types [32-35].
Demethylating agents have been reported to restore
PTEN expression in cell lines with hypermethylated
PTEN [5,6]. However, PTEN protein expression did not
change with decitabine exposure in ovarian cancer cell
lines [36], and the role of promoter hypermethylation in
silencing PTEN expression is not clear-cut. While the
above studies suggested a role for PTEN promoter hyper-
methylation, several other studies across a range of malig-
nancies have failed to detect significant PTEN promoter
methylation [37-40]. It has been noted that the PTENP1
pseudogene (that has 98% homology with PTEN) is fre-
quently hypermethylated in tumors and cell lines, while
PTEN is not, and reports of methylation of PTEN have
been attributed by some authors to misinterpretations
of hypermethylation of PTENP1 [38].
Results
Patient characteristics
Patient characteristics are presented in more detail in an
earlier publication on this patient group [8]. Patient
numbers varied slightly between tumor suppressor genes
since insufficient biopsy material was available for some
assessments. Twenty-five of 31 patients who were initially
entered on our decitabine phase I clinical trial [8] had suf-
ficient tissue to permit at least one IHC assessment (either
pre- or post-decitabine) of at least one of the four tumor
suppressor genes of interest. These 25 patients included
14 males and 11 females, with a median (range) age of 53
(20 to 75) years. Tumor types included cancers of the
breast (four patients), kidney (three), head and neck (three,
including one adenocystic carcinoma), lung (one), stom-
ach (one), and appendix (one), malignant melanomas
(four), thymic neoplasms (three), neuroendocrine tumors
(two), lymphomas (two), and desmoplastic tumor (one).
Patients had received a median (range) of five (1 to 14)
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6) prior targeted agents.
Tumor suppressor gene immunohistochemistry scores
versus time from last therapy
Comparing patients undergoing pre-decitabine tumor
biopsy ≤3 months after last prior chemotherapy or tar-
geted therapy to those undergoing initial biopsy >3 months
after last therapy are presented, PTEN scores were signifi-
cantly higher in patients with longer time intervals since
last treatment (P = 0.007), and there was a trend towards
higher FUS1 scores in later biopsies (P = 0.15), while there
was no association of FHIT and WWOX scores with time
from last treatment.
Tumor suppressor gene immunohistochemistry scores
versus LINE-1 methylation
Tumor suppressor gene scores did not correlate signifi-
cantly with LINE-1 methylation in pre-decitabine tumor
samples, nor in pre-and post-decitabine samples combined
(Table 1). However, if pre-decitabine scores for FHIT,
FUS1 and WWOX were considered together, tumors with
IHC scores = 0 for one of these genes (eight observations)
had significantly higher LINE-1 methylation than did
tumors with IHC scores >0 (58 observations) (median
61.6% versus 45.4%, P = 0.0481).
Decitabine effect on tumor suppressor gene
immunohistochemistry scores
For tumors with initially low tumor suppressor gene
IHC expression (scores ≤150), expression was higher post-
decitabine than pre-decitabine for FHIT (P = 0.0140), with
a trend to higher expression post-decitabine for WWOX
(P = 0.0547) and FUS1 (P = 0.0726), and little effect for
PTEN (P = 0.2034) (Table 2, Figure 1). Overall, for pre-
decitabine scores of ≤150, there was an increase in the
score post-decitabine in 8 of 8 cases for FHIT, 7 of 17 for
WWOX, 7 of 12 for FUS1, but only 1 of 16 for PTEN.
The proportion of cases with a post-decitabine increase
was significantly higher for FHIT, WWOX and FUS1
combined than for PTEN (P = 0.003 by Fisher’s exact test).
If FHIT, WWOX and FUS1 were considered together
then, for cases with initial scores ≤150, the medianTable 1 Correlation of tumor suppressor gene encoded
proteins with LINE-1 methylation (pre- and post-decitabine)
Protein n Spearman r P
FHIT 41 −0.23 0.15
WWOX 44 0.09 0.57
FUS1 41 0.15 0.35
PTEN 40 0.03 0.83
FHIT, fragile histidine triad; FUS1, fused in sarcoma-1; LINE-1, long interspersed
nuclear element-1; PTEN, phosphatase and tensin homolog; WWOX, WW
domain-containing oxidoreductase.scores pre- and post-decitabine were 60 and 100, re-
spectively (P = 0.0002).
Of those tumors that initially stained negatively for a
tumor suppressor gene (pre-decitabine score = 0), there
was conversion to positive staining post-decitabine for
FHIT in 1 of 1 patients, for WWOX in 3 of 6 patients,
for FUS1 in 2 of 3 patients, and for PTEN in 1 of 10
patients.
Post-decitabine changes in tumor suppressor gene
immunohistochemistry scores versus percentage changes
in LINE-1 DNA methylation
While there was a weak negative correlation between
percentage change in LINE-1 methylation and IHC score
for each tumor suppressor gene, this did not achieve sig-
nificance (Table 3). If we only considered tumors that
initially stained negatively for a gene, there was a stron-
ger trend (P = 0.069) for ones that converted from nega-
tive to positive staining with decitabine to have a greater
decrease in LINE-1 methylation with decitabine (median
decrease of 24% in LINE-1 methylation) than for those
that did not convert (median decrease in LINE-1 methy-
lation of 6%).
Tumor suppressor gene immunohistochemistry score
changes and tumor regression
Of the 25 patients included, both change in tumor size
with the first cycle of therapy and change in IHC scores
for all four tumor suppressor genes could be assessed in
15 patients. Of these, 10 patients had immediate tumor
growth, while five patients had a reduction in tumor
diameter of 0.2%, 2%, 4.7%, 22.1% and 33.4%, respect-
ively. Among the five with any degree of tumor regres-
sion, all five had increases in FHIT scores, three had
increases in WWOX scores, three had increases in FUS1
scores, and one had an increase in PTEN score. All five
had an increase in at least one tumor suppressor gene,
and three had simultaneous increases in three tumor
suppressor genes (including the two patients with the
greatest tumor regression), compared to 2 of 10 fully
evaluable patients with tumor growth who had an in-
crease in expression of three tumor suppressor genes
(P = 0.25 by Fisher’s exact test). Median (range) number of
tumor suppressor genes increasing with decitabine was
three (1 to 3) in those with tumor regression versus
two (0 to 3) in fully evaluable patients with tumor
growth (P = 0.34).
Discussion
In our phase I trial of the demethylating agent decitabine
we had previously reported that percentage LINE-1
DNA methylation correlated inversely with expression of
the copper/platinum transporter CTR1 and the endo-
cytosis regulator RhoA, and that decitabine treatment
Table 2 Median tumor suppressor gene encoded protein scores post- versus pre-decitabine for patients with
pre-decitabine scores (≤150), and number of patients with an increase, no change or decrease in scores with decitabine
Protein n Score pre-decitabine Score post-decitabine P Number with
increase in score
Number with no
change in score
Number with
decrease in score
FHIT 8 100 175 0.014 8 0 0
WWOX 17 30 100 0.05 7 8 2
FUS1 12 67.5 100 0.07 7 2 3
PTEN 16 0 0 0.20 1 10 5
FHIT, WWOX or FUS1 37 60 100 0.0002 22 10 5
FHIT, fragile histidine triad; FUS1, fused in sarcoma-1; PTEN, phosphatase and tensin homolog; WWOX, WW domain-containing oxidoreductase.
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RhoA and of the folate carrier RFC1 in patients in whom
expression was initially low [8,9]. Early phase clinical tri-
als also suggest that addition of decitabine to a platinum
agent may partially reverse platinum-resistance in ad-
vanced ovarian carcinomas [41-43]. Hence, there is inter-
est in further exploring the role of decitabine and other
demethylating agents as resistance-modulating therapies.
In this further assessment of patients included in our
phase I trial of low-dose single-agent decitabine, we
assessed the impact of decitabine on expression of selected
tumor suppressor genes. Loss of tumor suppressor gene
function through gene deletion, mutation, or silencing
(through promoter hypermethylation or other means) isFHIT post- vs pre-decitabine (for pre <150)
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Figure 1 Change in immunohistochemistry scores for fragile histidine
fused in sarcoma-1 (FUS1) and phosphatase and tensin homolog (PTE
(≤150). By Wilcoxon matched pairs signed rank tests, there was a significan
median scores 175 versus 100, P = 0.0140), with a strong trend towards an
versus 30, P = 0.0547) and FUS1 (post- versus pre-decitabine median scores
(post- versus pre-decitabine scores 0 versus 0, P = 0.2034). Medians are indiimportant in tumorigenesis, but replacing lost tumor sup-
pressor gene function is difficult. Attempts at tumor sup-
pressor gene replacement by adenovirus-mediated gene
therapy have met with modest early indications of success
[44-46], although administration has generally been by
local injection or similar means, and systemic delivery to
widespread metastases is challenging. However, it has re-
cently been demonstrated that intravenous administration
of the tumor suppressor gene FUS1/TUSC2 in DOTAP
nanoparticles is capable of systemic delivery to dissemi-
nated disease [47], and this approach is undergoing further
investigation.
Our results with decitabine suggest that demethylating
agents may be capable of upregulating expression ofWWOX post- vs pre-decitabine (for pre <150)
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triad (FHIT), WW domain-containing oxidoreductase (WWOX),
N) with decitabine for tumors with scores that were initially low
t increase in FHIT scores with decitabine (post- versus pre-decitabine
increase in WWOX (post- versus pre-decitabine median scores 100
100 versus 67.5, P = 0.0726), but with no major change in PTEN
cated by horizontal lines on the graphs.
Table 3 Change in tumor suppressor gene encoded
protein score versus percentage change in LINE-1
methylation with decitabine
Protein n Spearman r P
FHIT 16 −0.34 0.19
WWOX 19 −0.04 0.87
FUS1 16 −0.03 0.91
PTEN 15 −0.26 0.36
Any tumor suppressor gene 67 −0.11 0.39
FHIT, fragile histidine triad; FUS1, fused in sarcoma-1; PTEN, phosphatase and
tensin homolog; WWOX, WW domain-containing oxidoreductase.
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patient numbers have limited statistical power but, des-
pite this, there was a statistically significant increase in
expression of FHIT following decitabine, with a strong
statistical trend towards increase in expression of WWOX
and FUS1, and combining data for FHIT, WWOX and
FUS1 indicated a significant increase in IHC expression of
these three tumor suppressor genes together. This is suffi-
cient to encourage further assessment of the ability of
demethylating agents to restore tumor suppressor gene
function in situations where it has been decreased or lost
due to promoter hypermethylation. For each of these
tumor suppressor genes, available published data suggest
that promoter methylation may be an important cause of
loss of gene function [3,4,12-17,25-27,29,48,49], although
we did not have sufficient residual tissue to permit us to
assess this in our study, and it is probable that other
mechanisms such as gene deletion or mutation were re-
sponsible for low expression in a proportion of the tu-
mors. We also did not have sufficient tissue available to
assess whether increase in tumor suppressor gene protein
expression with decitabine was associated with reduction
in tumor suppressor gene DNA methylation.
There was no apparent increase in PTEN IHC scores
with decitabine treatment, and changes in PTEN scores
were significantly lower than changes in scores for the
other tumor suppressor genes. This is in keeping with
the indication from many publications that promoter
methylation may not be an important cause of loss of
PTEN expression [37-39], and in keeping with the hy-
pothesis that an apparent role for PTEN promoter
methylation may be due to misinterpretation of data
arising from methylation of the closely related pseudo-
gene PTENP1 [38]. An additional potential explanation
for the lack of impact of decitabine on PTEN is that, for
at least some genes, gene reactivation in response to
decitabine requires chromatin remodeling in addition to
DNA demethylation if histone modification is playing a
role in gene silencing [50].
All five patients experiencing tumor regression with
decitabine had an increase in the IHC score of at leastone tumor suppressor gene, and three (including the
two with the greatest regression) had an increase in IHC
scores of three tumor suppressor genes, compared to 2
of 10 fully evaluable patients who had tumor growth who
had an increase in IHC scores for three tumor suppressor
genes, and the median number of tumor suppressor genes
that increased with decitabine was three in patients with
tumor regression versus two in patients with tumor
growth. Further assessment will be needed to determine if
change in tumor suppressor genes with decitabine impacts
the probability of achieving tumor regression.
Conclusions
Overall, our data add further evidence that exploration
of demethylating agents in solid tumors may be of
interest. It may be of particular interest to explore
them in tumors that are demonstrated to have low ex-
pression of tumor suppressor genes in association with
promoter methylation.
Methods
This study was approved by the MD Anderson Cancer
Center Research Ethics Board, and recruited consenting
patients with advanced malignancies, tumors that could
be safely biopsied, and organ function meeting eligibility
requirements [8]. Decitabine was supplied under a Col-
laborative and Research Development Agreement by the
National Cancer Institute Division of Cancer Treatment
and Diagnosis. Decitabine doses of 2.5, 5, or 10 mg/m2/
day on days 1 to 5 and 8 to 12 each 4-week cycle or 15
or 20 mg/m2/day on days 1 to 5 each cycle were admin-
istered over 1 hour, with filgrastim added at higher
doses [8].
Tumor biopsies were performed pre-decitabine and on
day 12, cycle 1 [8]. Formalin-fixed, paraffin-embedded
tissue sections (5 μm thick) were deparaffinized in Xylene
(10 minutes × 3), followed by hydration in sequenced
graded alcohols (5 minutes each). Heat-induced epitope
retrieval was performed in DAKO solution for 30 minutes
at 121°C, followed by 10 minutes at 90°C using a
Decloaking chamber (Biocare, Concord, CA), followed
by a 30-minute cool-down. Prior to antibody immuno-
staining, endogenous peroxidase activity was blocked
with 3% hydrogen peroxide in methanol for 30 minutes.
To block non-specific antibody binding, tissues were in-
cubated in 10% fetal bovine serum/Tris-buffered saline
with Tween 20 for 30 minutes. Primary incubation anti-
bodies are presented in Table 4. This was followed by
incubation with Envision plus labeled polymer, anti-
rabbit-horseradish peroxidase antibody (DAKO, Carpin-
teria, CA) for 30 minutes at room temperature. The
FUS1 protocol was as previously described [47]. Time
monitoring staining development was performed with
diaminobenzidine, using a reliable positive control sample.
Table 4 Antibodies used for immunohistochemistry
Protein Source Dilution
FHIT Thermo Scientific, Waltham, MA, USA 1:100
WWOX Abcam, Cambridge, MA, USA 1:100
FUS1 Homemade, rabbit polyclonal 1:400
PTEN Cell Signaling, Danvers, MA, USA 1:75
FHIT, fragile histidine triad; FUS1, fused in sarcoma-1; PTEN, phosphatase and
tensin homolog; WWOX, WW domain-containing oxidoreductase.
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cleared and mounted.
Participating pathologist MIN scored staining intensity
as 0 to 3+ and generated IHC scores of 0 to 300 by
multiplying the percent of tumor cells staining by the
staining intensity. For PTEN, we assessed both cytoplas-
mic and nuclear staining scores, but report only on the
cytoplasmic scores since results were similar for the two
staining sites. Change in IHC score was defined as the
day 12 score minus the day 1 score.
As previously reported, the LINE-1 assay was used to
define percentage of DNA CpG islands that were meth-
ylated, as a surrogate for global DNA methylation [8,51].
Change in LINE-1 methylation was defined as the day
12 value minus the day 1 value divided by the day 1
value.
While low patient numbers limited statistical power,
GraphPad Prism 5.0 (GraphPad Software, San Diego,
CA) was used to assess non-parametric two-tailed statis-
tics (Spearman tests for correlations, Wilcoxon signed
rank tests for paired comparisons, and Mann–Whitney
tests and Fisher exact tests for comparisons of two
groups).
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